Nedaplatin
- Generic Name
- Nedaplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C2H8N2O3Pt
- CAS Number
- 95734-82-0
- Unique Ingredient Identifier
- 8UQ3W6JXAN
- Background
Nedaplatin is a second generation platinum analog . It is less nephrotoxic than Cisplatin but has proven equally effective. It was approved for use in Japan in 1995.
- Indication
Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers .
- Associated Conditions
- -
- Associated Therapies
- -
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 65
- Registration Number
- NCT06508229
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 46
- Registration Number
- NCT06170697
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 272
- Registration Number
- NCT06102395
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT05515315
- Locations
- 🇨🇳
Ye zai sheng, Fuzhou, Fujian, China
Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Guiyang Medical University
- Target Recruit Count
- 164
- Registration Number
- NCT05039606
- Locations
- 🇨🇳
The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 124
- Registration Number
- NCT04844385
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-05-10
- Target Recruit Count
- 32
- Registration Number
- NCT04834206
- Locations
- 🇨🇳
Department of radiotherapy(Section 5),Affiliated Cancer Hospital & Institute of Guangzhou Medical Universityedical University, Guangzhou, Guangdong, China
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2022-05-10
- Target Recruit Count
- 352
- Registration Number
- NCT04437329
- Locations
- 🇨🇳
Department of radiotherapy(Section 5),Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2018-08-28
- Target Recruit Count
- 186
- Registration Number
- NCT03649945
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 45
- Registration Number
- NCT03603756
- Locations
- 🇨🇳
Jing Huang, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.